Capstone Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.04M | Sell |
4,761
-472
| -9% | -$105K | ﹤0.01% | 854 |
|
|
2025
Q4 | $1.2M | Sell |
5,233
-7,010
| -57% | -$1.6M | ﹤0.01% | 799 |
|
|
2025
Q3 | $2.83M | Sell |
12,243
-27,149
| -69% | -$5.53M | 0.01% | 642 |
|
|
2025
Q2 | $7.31M | Buy |
39,392
+34,335
| +679% | +$6.38M | 0.02% | 316 |
|
|
2025
Q1 | $1.06M | Sell |
5,057
-20,334
| -80% | -$3.95M | ﹤0.01% | 872 |
|
|
2024
Q4 | $4.51M | Buy |
25,391
+23,855
| +1,553% | +$4.39M | 0.01% | 586 |
|
|
2024
Q3 | $303K | Buy |
+1,536
| New | +$287K | ﹤0.01% | 1412 |
|
|
2024
Q2 | – | Sell |
-5,971
| Closed | -$989K | – | 2034 |
|
|
2024
Q1 | $1.09M | Buy |
5,971
+5,750
| +2,602% | +$991K | ﹤0.01% | 1096 |
|
|
2023
Q4 | $34.2K | Sell |
221
-21,442
| -99% | -$3.13M | ﹤0.01% | 2025 |
|
|
2023
Q3 | $3.23M | Sell |
21,663
-34,510
| -61% | -$5.07M | 0.01% | 556 |
|
|
2023
Q2 | $7.57M | Buy |
+56,173
| New | +$8.24M | 0.04% | 291 |
|
|
2023
Q1 | – | Sell |
-21
| Closed | -$3.21K | – | 1543 |
|
|
2022
Q4 | $3.39K | Sell |
21
-18,538
| -100% | -$2.84M | ﹤0.01% | 1485 |
|
|
2022
Q3 | $2.49M | Sell |
18,559
-1,539
| -8% | -$221K | 0.02% | 672 |
|
|
2022
Q2 | $3.08M | Buy |
20,098
+3,075
| +18% | +$470K | 0.02% | 588 |
|
|
2022
Q1 | $2.76M | Buy |
17,023
+15,285
| +879% | +$2.22M | 0.01% | 917 |
|
|
2021
Q4 | $235K | Sell |
1,738
-76,220
| -98% | -$9M | ﹤0.01% | 1560 |
|
|
2021
Q3 | $8.41M | Buy |
77,958
+42,724
| +121% | +$4.88M | 0.02% | 679 |
|
|
2021
Q2 | $3.97M | Buy |
+35,234
| New | +$3.97M | 0.01% | 787 |
|
|
2020
Q4 | – | Sell |
-329
| Closed | -$31.6K | – | 1658 |
|
|
2020
Q3 | $29K | Buy |
+329
| New | +$31K | ﹤0.01% | 1370 |
|
|
2020
Q1 | – | Sell |
-43,370
| Closed | -$3.69M | – | 1109 |
|
|
2019
Q4 | $3.84M | Sell |
43,370
-2,110
| -5% | -$175K | 0.02% | 655 |
|
|
2019
Q3 | $3.44M | Buy |
45,480
+19,288
| +74% | +$1.32M | 0.02% | 568 |
|
|
2019
Q2 | $1.91M | Buy |
26,192
+9,156
| +54% | +$720K | 0.01% | 755 |
|
|
2019
Q1 | $1.37M | Buy |
17,036
+10,044
| +144% | +$822K | 0.01% | 719 |
|
|
2018
Q4 | $645K | Sell |
6,992
-15,086
| -68% | -$1.33M | 0.01% | 753 |
|
|
2018
Q3 | $2.09M | Buy |
22,078
+12,767
| +137% | +$1.21M | 0.02% | 428 |
|
|
2018
Q2 | $863K | Buy |
+9,311
| New | +$909K | 0.01% | 403 |
|
|
2016
Q4 | – | Sell |
-18,600
| Closed | -$1.14M | – | 890 |
|
|
2016
Q3 | $1.17M | Buy |
+18,600
| New | +$1.2M | 0.03% | 349 |
|
|
2016
Q1 | – | Sell |
-10,956
| Closed | -$649K | – | 627 |
|
|
2015
Q4 | $649K | Buy |
+10,956
| New | +$631K | 0.02% | 308 |
|
Other funds holding ABBV
VCM
VPM
Capstone Investment Advisors's ABBV Position: Q1 2026 in Review
Capstone Investment Advisors reduced its AbbVie (ABBV) stake by 9% in Q1 2026, selling an estimated $105K and leaving 4,761 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #854.
Capstone Investment Advisors first reported a position in ABBV in Q4 2015 and has held it in 28 quarters since. The position peaked at $8.41M in Q3 2021. 4,092 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Capstone Investment Advisors held 4,761 shares of AbbVie worth $1.04M as of Q1 2026.
- Capstone Investment Advisors sold 472 AbbVie shares in Q1 2026, an estimated $105K.
- AbbVie made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #854 holding.
- Capstone Investment Advisors first reported a position in AbbVie in Q4 2015 and has held it in 28 quarters since.
- Capstone Investment Advisors's AbbVie position peaked at $8.41M in Q3 2021.
- 4,092 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.